Gianluigi, S., Felix, L., Antonio, C., Marianna, A., Giuseppe, A., Pietro, A., S, A.M., Magnus, B., Antoni, B.G., Tuvia, B.G., Frieder, B., Ovidiu, C., Emilia, D., Hassan, E.T., Gerasimos, F., Nicolas, G., Loreena, H., Ewa, J., Kamlesh, K., . . . C, R.G.M. (2025). Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy.. European journal of heart failure. https://doi.org/10.1002/ejhf.70090
Gianluigi S, Felix L, Antonio C, Marianna A, Giuseppe A, Pietro A, et al. Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy.. European journal of heart failure. 2025; doi: 10.1002/ejhf.70090
Gianluigi S, Felix L, Antonio C, et al. Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy.[J]. European journal of heart failure. 2025. DOI: 10.1002/ejhf.70090.
@article{gianluigi2025,
author = {Savarese Gianluigi and Lindberg Felix and Cannata Antonio and Adamo Marianna and Ambrosio Giuseppe and Ameri Pietro and Anker Markus S and Bäck Magnus and Bayes-Genis Antoni and Ben Gal Tuvia and Braunschweig Frieder and Chioncel Ovidiu and D'Elia Emilia and El-Tamimi Hassan and Filippatos Gerasimos and Girerd Nicolas and Hill Loreena and Jankowska Ewa and Khunti Kamlesh and Lewis Basil S and Moura Brenda and Amir Offer and Paolillo Stefania and Piepoli Massimo and Shehab Abdulla and Simpson Maggie and Skouri Hadi and Stolfo Davide and Tocchetti Carlo Gabriele and Vitale Cristiana and Volterrani Maurizio and von Haehling Stephan and Wassmann Sven and Yilmaz Mehmet Birhan and Kaski Juan Carlos and Dobrev Dobromir and Metra Marco and Rosano Giuseppe M C},
title = {Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy.},
journal = {European journal of heart failure},
year = {2025},
doi = {10.1002/ejhf.70090},
note = {PMID: 41208145},
}
TY - JOUR AU - Savarese Gianluigi AU - Lindberg Felix AU - Cannata Antonio AU - Adamo Marianna AU - Ambrosio Giuseppe AU - Ameri Pietro AU - Anker Markus S AU - Bäck Magnus AU - Bayes-Genis Antoni AU - Ben Gal Tuvia AU - Braunschweig Frieder AU - Chioncel Ovidiu AU - D'Elia Emilia AU - El-Tamimi Hassan AU - Filippatos Gerasimos AU - Girerd Nicolas AU - Hill Loreena AU - Jankowska Ewa AU - Khunti Kamlesh AU - Lewis Basil S AU - Moura Brenda AU - Amir Offer AU - Paolillo Stefania AU - Piepoli Massimo AU - Shehab Abdulla AU - Simpson Maggie AU - Skouri Hadi AU - Stolfo Davide AU - Tocchetti Carlo Gabriele AU - Vitale Cristiana AU - Volterrani Maurizio AU - von Haehling Stephan AU - Wassmann Sven AU - Yilmaz Mehmet Birhan AU - Kaski Juan Carlos AU - Dobrev Dobromir AU - Metra Marco AU - Rosano Giuseppe M C TI - Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy. T2 - European journal of heart failure PY - 2025 DO - 10.1002/ejhf.70090 AN - PMID:41208145 ER -
Heart failure (HF) affects over 60 million individuals globally. Contemporary guideline-directed medical therapies (GDMT) reduce cardiovascular mortality and HF hospitalizations. However, medication non-adherence represents a critical barrier limiting real-world efficacy of GDMT. This scientific statement aims to provide a comprehensive framework for understanding, measuring, and addressing medication non-adherence in HF management across diverse healthcare settings. Addressing medication non-adherence requires systematic, multifaceted approaches targeting individual patient barriers while implementing system-level interventions. Polypills, digital monitoring platforms, enhanced patient education and empowerment, and multidisciplinary care models represent promising strategies to optimize therapeutic adherence and improve clinical outcomes in HF management.